


**DESCRIPTION**

|                                   |  |
|-----------------------------------|--|
| <i>Description</i>                | Recombinant Human B Cell Maturation Protein (BCMA)   |
| <i>Sequence</i>                   | Native NCBI Accession Number: Q02223<br>Leu2-Ala54 (Extra Cellular Domain)                                       |
| <i>Expression system</i>          | HEK293 cells   |
| <i>Tag</i>                        | Silent Human IgG1 Fc (Pro100-Lys330)   |
| <i>Purification</i>               | Affinity chromatography  |
| <i>Extinction coefficient</i>     | 39140 M <sup>-1</sup> .cm <sup>-1</sup> Abs 0.1% (=1 g/l) 1.216 assuming all pairs of Cys residues form cystines |
| <i>Predicted Molecular Weight</i> | 32.2 kDa   |

**SPECIFICATIONS**

|                              |   |
|------------------------------|---|
| <i>SDS Page</i>              | Approx.37 kDa (monomer, reducing conditions)              |
| <i>Concentration</i>         | 1 mg/ml   |
| <i>Purity</i>                | >90% by SDS PAGE gel                                      |
| <i>Formulation</i>           | Liquid PBS  |
| <i>Activity</i>              | Recognized by B-B54 clone (anti-BCMA) in Elisa            |
| <i>Stability and Storage</i> | Store at minimum -20°C. Avoid repeated freeze-thaw cycles |

**DATA**



**B Cell Maturation Protein**

B-cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a receptor preferentially expressed in mature B lymphocytes, and is important for B cell development and autoimmune response.

BCMA, along with two related TNFR superfamily B-cell activation factor receptor (BAFF-R) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), critically regulate B cell proliferation and survival, as well as maturation and differentiation into plasma cells [1]. BCMA is highly expressed on the surface of the malignant plasma cells that characterize this cancer type. BCMA is a promising novel target for antimyeloma therapies [2].

**BIBLIOGRAPHY**

1. Cho S.F, Anderson K.C and Tai Y.T. (2018). Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. *Front. Immunol.* 9:1821. doi: 10.3389/fimmu.2018.01821
2. Shah, N., Chari, A., Scott, E. et al. (2020). B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. *Leukemia* 34, 985–1005. <https://doi.org/10.1038/s41375-020-0734-z>

Products Manufactured and Distributed by:  
Diacclone SAS – Part of Medix Biochemica Group  
6 Rue Dr Jean-François-Xavier Girod  
BP 1985, 25020 Besançon Cedex  
France  
Tel +33 (0)3 81 41 38 38  
Email: [info@diacclone.com](mailto:info@diacclone.com) [www.diacclone.com](http://www.diacclone.com)